



Supernus Pharmaceuticals, Inc.  
Investor Relations Department  
1550 East Gude Drive  
Rockville, MD 20850  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: SUPN**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 55.65                      |
| Trade Time:   | 4:00 PM ET<br>May 24, 2018 |
| Change:       | 0.70  (+1.274%)            |
| Day Range     | 54.70 - 55.75              |
| 52-Week Range | 33.30 - 59.05              |
| Volume        | 589,163                    |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- May 8, 2018*  
[Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue](#)
- Apr 24, 2018*  
[Supernus to Host First Quarter 2018 Earnings Conference Call](#)
- Mar 15, 2018*  
[Supernus Announces Pricing of \\$350 Million Private Offering of 0.625% Convertible Senior Notes](#)
- Mar 13, 2018*  
[Supernus Announces Proposed Private Offering of \\$350 Million of Convertible Senior Notes](#)
- Mar 6, 2018*  
[Supernus to Present at the 2018 Cowen Health Care Conference](#)

## Financials & Filings [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 1, 2018*  
[Annual Report \(10-K\)](#)
- Apr 27, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2018*  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)